vs
Side-by-side financial comparison of Outset Medical, Inc. (OM) and TRINITY BIOTECH PLC (TRIB). Click either name above to swap in a different company.
TRINITY BIOTECH PLC is the larger business by last-quarter revenue ($30.5M vs $28.9M, roughly 1.1× Outset Medical, Inc.). TRINITY BIOTECH PLC runs the higher net margin — -33.0% vs -67.5%, a 34.5% gap on every dollar of revenue. TRINITY BIOTECH PLC produced more free cash flow last quarter ($-4.1M vs $-9.7M).
Outset Medical, Inc. is a medical technology company focused on developing and commercializing innovative dialysis solutions for patients living with kidney disease. Its flagship Tablo Hemodialysis System supports use in acute care facilities, outpatient clinics, and home settings, serving healthcare providers and patients across the U.S. and select international markets.
Trinity Biotech PLC develops, manufactures and markets diagnostic test kits and systems for clinical laboratories and point-of-care settings. Its product portfolio covers diabetes management, infectious diseases, cardiac health, autoimmune disorders and coagulation, with core markets across North America, Europe and emerging economies.
OM vs TRIB — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $28.9M | $30.5M |
| Net Profit | $-19.5M | $-10.1M |
| Gross Margin | 42.4% | 36.8% |
| Operating Margin | -61.1% | -23.2% |
| Net Margin | -67.5% | -33.0% |
| Revenue YoY | -2.0% | — |
| Net Profit YoY | 24.0% | — |
| EPS (diluted) | $0.33 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.9M | — | ||
| Q3 25 | $29.4M | — | ||
| Q2 25 | $31.4M | — | ||
| Q1 25 | $29.8M | — | ||
| Q4 24 | $29.5M | — | ||
| Q3 24 | $28.7M | — | ||
| Q2 24 | $27.4M | $30.5M | ||
| Q1 24 | $28.2M | — |
| Q4 25 | $-19.5M | — | ||
| Q3 25 | $-17.8M | — | ||
| Q2 25 | $-18.5M | — | ||
| Q1 25 | $-25.8M | — | ||
| Q4 24 | $-25.6M | — | ||
| Q3 24 | $-27.9M | — | ||
| Q2 24 | $-34.5M | $-10.1M | ||
| Q1 24 | $-39.9M | — |
| Q4 25 | 42.4% | — | ||
| Q3 25 | 39.4% | — | ||
| Q2 25 | 37.8% | — | ||
| Q1 25 | 37.2% | — | ||
| Q4 24 | 36.5% | — | ||
| Q3 24 | 34.3% | — | ||
| Q2 24 | 35.7% | 36.8% | ||
| Q1 24 | 29.2% | — |
| Q4 25 | -61.1% | — | ||
| Q3 25 | -53.7% | — | ||
| Q2 25 | -53.7% | — | ||
| Q1 25 | -55.1% | — | ||
| Q4 24 | -74.2% | — | ||
| Q3 24 | -83.2% | — | ||
| Q2 24 | -112.3% | -23.2% | ||
| Q1 24 | -131.0% | — |
| Q4 25 | -67.5% | — | ||
| Q3 25 | -60.6% | — | ||
| Q2 25 | -59.0% | — | ||
| Q1 25 | -86.7% | — | ||
| Q4 24 | -87.0% | — | ||
| Q3 24 | -97.5% | — | ||
| Q2 24 | -125.8% | -33.0% | ||
| Q1 24 | -141.8% | — |
| Q4 25 | $0.33 | — | ||
| Q3 25 | $-1.00 | — | ||
| Q2 25 | $-1.04 | — | ||
| Q1 25 | $-3.66 | — | ||
| Q4 24 | $-7.21 | — | ||
| Q3 24 | $-8.02 | — | ||
| Q2 24 | $-9.96 | — | ||
| Q1 24 | $-11.77 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $168.9M | $5.3M |
| Total DebtLower is stronger | $96.2M | — |
| Stockholders' EquityBook value | $127.0M | $-29.4M |
| Total Assets | $264.5M | $94.4M |
| Debt / EquityLower = less leverage | 0.76× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $168.9M | — | ||
| Q3 25 | $178.6M | — | ||
| Q2 25 | $184.1M | — | ||
| Q1 25 | $189.0M | — | ||
| Q4 24 | $158.7M | — | ||
| Q3 24 | $175.6M | — | ||
| Q2 24 | $194.8M | $5.3M | ||
| Q1 24 | $226.9M | — |
| Q4 25 | $96.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $197.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $127.0M | — | ||
| Q3 25 | $142.4M | — | ||
| Q2 25 | $154.8M | — | ||
| Q1 25 | $169.9M | — | ||
| Q4 24 | $26.8M | — | ||
| Q3 24 | $47.8M | — | ||
| Q2 24 | $68.6M | $-29.4M | ||
| Q1 24 | $93.2M | — |
| Q4 25 | $264.5M | — | ||
| Q3 25 | $277.3M | — | ||
| Q2 25 | $288.8M | — | ||
| Q1 25 | $301.2M | — | ||
| Q4 24 | $275.8M | — | ||
| Q3 24 | $292.9M | — | ||
| Q2 24 | $314.5M | $94.4M | ||
| Q1 24 | $346.2M | — |
| Q4 25 | 0.76× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.36× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.5M | $-3.9M |
| Free Cash FlowOCF − Capex | $-9.7M | $-4.1M |
| FCF MarginFCF / Revenue | -33.7% | -13.3% |
| Capex IntensityCapex / Revenue | 0.8% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-47.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.5M | — | ||
| Q3 25 | $-6.3M | — | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $-25.7M | — | ||
| Q4 24 | $-16.5M | — | ||
| Q3 24 | $-20.6M | — | ||
| Q2 24 | $-33.3M | $-3.9M | ||
| Q1 24 | $-45.9M | — |
| Q4 25 | $-9.7M | — | ||
| Q3 25 | $-6.5M | — | ||
| Q2 25 | $-5.1M | — | ||
| Q1 25 | $-25.8M | — | ||
| Q4 24 | $-16.5M | — | ||
| Q3 24 | $-21.0M | — | ||
| Q2 24 | $-33.5M | $-4.1M | ||
| Q1 24 | $-46.3M | — |
| Q4 25 | -33.7% | — | ||
| Q3 25 | -22.0% | — | ||
| Q2 25 | -16.3% | — | ||
| Q1 25 | -86.7% | — | ||
| Q4 24 | -56.1% | — | ||
| Q3 24 | -73.1% | — | ||
| Q2 24 | -122.2% | -13.3% | ||
| Q1 24 | -164.3% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 1.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OM
| Consumables Product | $13.5M | 47% |
| Service And Other Revenue | $9.0M | 31% |
| Consoles Product | $6.4M | 22% |
TRIB
Segment breakdown not available.
